Next, by considering the combined biomarkers, we defined two molecular metabolism phenotypes of colon cancer: a glycolysis‐proficient phenotype (glycolysis+) with either GLUT1 or PFKFB3 overexpression and a ketolysis‐deficient (ketolysis−) phenotype by null expression of either OXCT1 or ACAT1. Here, SLC2A1 is linked to malignant colon neoplasm.